Addex Pharmaceuticals and a subsidiary of Merck & Co have agreed to extend for a third year their collaboration on developing positive allosteric modulators (PAMs) for a receptor linked with Parkinson’s disease. ---Subscribe to MedNous to access this article--- Company News
